S&P 500 Surges Amid Election Drama

This is a news story, published by Yahoo Finance, that relates primarily to Strong Buys news.

Strong Buys news

For more Strong Buys news, you can click here:

more Strong Buys news

stocks trading & speculation news

For more stocks trading & speculation news, you can click here:

more stocks trading & speculation news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about

strong investor confidence

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest bullish election news, recent positive analyst reviews news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Best Stocks

TipRanks

•

Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks

Summary

Nutrition label

79% Informative

Morgan Stanley’s analysts are embracing this momentum, picking out stocks they believe are primed for gains regardless of the election outcome.

They’ve zeroed in on two specific stocks poised for substantial growth in the coming year including one with a potential upside as high as 670% . Both stocks are also rated as Strong Buys by the analyst consensus.

Royalty Pharma enjoys unanimous support, with 5 Buy ratings and a Strong Buy consensus.

Morgan Stanley analyst Terence Flynn takes an upbeat view of the company and its prospects for the long-term.

Currently priced at $ 27.10 , the stock’s average price target of $ 44.40 implies a 64% upside in the coming months .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language